share_log

上海医药(601607.SH):终止I001-B(美国)、I022(美国)、C012(美国)项目

SH PHARMA (601607.SH): Termination of projects I001-B (USA), I022 (USA), C012 (USA).

Gelonghui Finance ·  Jan 1 16:58

On January 1, Gelonghui reported that SH PHARMA (601607.SH) announced to reasonably allocate R&D resources and focus on advantageous R&D projects. Based on a comprehensive evaluation of the future market value of R&D projects, business synergy, and subsequent development investments, SH PHARMA decided to terminate the clinical trials and further development of three R&D projects: I001-B (USA), I022 (USA), and C012 (USA). Among them, I001-B (USA) and I022 (USA) are in Phase II of clinical trials in the USA, while C012 (USA) has received Phase I clinical trial approval from the USA Food and Drug Administration (FDA).

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment